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Abstract
The epithelial to mesenchymal transition (EMT) has been well recognized for many decades as an essential early step in the
progression of primary tumors towards metastases. Widespread epigenetic reprogramming of DNA and histone
modifications tightly regulates gene expression and cellular activity during carcinogenesis, and epigenetic therapy has
been developed to design efficient strategies for cancer treatment. As the first oral agent approved for the clinical treatment
of cancer, sorafenib has significant inhibitory effects on tumor growth and EMT. However, a detailed understanding of the
underlying epigenetic mechanism remains elusive. In this manuscript, we performed a ChIP-seq assay to evaluate the
activity of sorafenib on the genome-wide profiling of histone modifications. We demonstrate that sorafenib largely reverses
the changes in histone modifications that occur during EMT in A549 alveolar epithelial cells. Sorafenib also significantly
reduces the coordinated epigenetic switching of critical EMT-associated genes in accordance with their expression levels.
Furthermore, we show that sorafenib potentiates histone acetylation by regulating the expression levels of histone-
modifying enzymes. Collectively, these findings provide the first evidence that sorafenib inhibits the EMT process through
an epigenetic mechanism, which holds enormous promise for identifying novel epigenetic candidate diagnostic markers
and drug targets for the treatment of human malignancies.
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Introduction
As one of the most common types of human diseases, cancer is
now the third leading cause of mortality in China and worldwide
for both men and women, and more than 90% of deaths from
cancer are due to the metastatic spread of primary tumors [1]. The
breakdown of epithelium homeostasis, which leads to aggressive
cancer progression, corresponds with the loss of epithelial
properties and the acquisition of migratory mesenchymal charac-
teristics, termed the epithelial-mesenchymal transition (EMT).
This transition is believed to be an essential step for carcinoma
invasion and metastasis [2,3]. In addition to the essential role that
this morphological transition plays in carcinogenesis, EMT has
also been widely recognized in the context of physiological and
pathological events such as embryonic development, wound
healing and organ fibrosis. Interestingly, during EMT process,
the loss of epithelial markers such as E-cadherin can occur through
genetic or epigenetic mechanisms including aberrant DNA
hypermethylation within the E-cadherin promoter [4]. This
finding suggests that a program of molecular alterations leading
to EMT, invasion and metastasis can be modulated epigenetically.
Epigenetic modifications, especially DNA methylation and
histone modifications, work in concert with genetic mechanisms
to regulate transcriptional activity in normal tissues. These
modifications emerge as a dynamic and efficacious mechanism
for the establishment and regulation of gene expression patterns
during development, differentiation and tumorigenesis [5,6]. Over
the last decade, the epigenetic contribution of certain genes that
are critical to EMT has been well studied. Notably, accumulating
evidence has indicated that genome-wide reprogramming of
histone modifications contributes to carcinogenesis and other
EMT-related diseases, while bulk chromatin is globally repro-
grammed during a pathological EMT [7,8]. Because epigenetics
has been found to be increasingly important in shaping the
phenotypic variation of a broad range of biological events, further
studies focusing on the mechanisms for epigenetic inheritance that
underlie physiological and pathological EMT are highly desirable.
These investigations may help us to identify epigenetically
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misregulated genes that can serve as diagnostic markers for
epigenetic therapeutic strategies for treating cancer.
Recently, the successful development of small chemicals that
disrupt several fundamental signaling pathways has signified a
paradigm shift in medical therapies [9]. In addition to this
established molecular-targeting strategy, insights into epigenetic
profiles that identify molecular mediators of cancer drug sensitivity
are leading to novel, promising means of prioritizing anti-cancer
therapies. As a small molecular inhibitor that targets a number of
serine/threonine and receptor tyrosine kinases, sorafenib (Nexavar
or BAY 43-9006) is the first oral agent approved for the clinical
treatment of a variety of tumor types [10,11]. Previously, we
uncovered a novel capacity of sorafenib to antagonize EMT and
cell migration [12]. However, a detailed understanding of the
underlying epigenetic mechanism is far from complete. In the
current study, we performed chromatin immunoprecipitation
followed by high throughput sequencing (ChIP-seq) to evaluate
the effects of sorafenib on the genome-wide profiling of four
selected histone modifications, and presented evidence that
sorafenib inhibited TGF-b1-induced EMT through the epigenetic
modulation of multiple EMT-associated genes in human alveolar
epithelial cells.
Results
Sorafenib Suppresses TGF-b1-induced EMT in A549
Alveolar Epithelial Cells
During metastasis, an increasing number of key growth factors
have been found to be responsible for driving EMT, of which
transforming growth factor-b (TGF-b) is a master inducer [13]. To
examine whether sorafenib could impair TGF-b-induced EMT in
epithelial cells, we used human A549 epithelial cells, a lung
adenocarcinoma cell line that has been extensively used and is an
ideal in vitro model for assessing EMT, carcinogenesis and drug
metabolism [14]. Alveolar epithelial A549 cells underwent EMT
after being exposed to TGF-b1 for 48 h, during which the cells lost
their epithelial honeycomb-like morphology and obtained a
spindle-like shape (Figure 1A). Along with these morphological
alterations, the expression level of the adherens junction protein E-
cadherin was decreased, whereas the expression level of the
intermediate filament protein fibronectin was up-regulated
(Figure 1B). Impressively, the treatment of A549 cells with
sorafenib mediated a cellular resistance to EMT, as shown by
cellular phenotypic alterations (Figure 1A) and the expression
profiles of EMT markers (Figure 1B). We also treated cells with
increasing concentrations of sorafenib under TGF-b1 stimulation.
As shown in Figure 1C, sorafenib reversed TGF-b1-induced EMT
in a dose-dependent manner. In addition, TGF-b1 provoked a
marked increase in the migratory capacity of A549 epithelial cells
that could also be abolished by sorafenib (Figure S1). Collectively,
these data indicate that sorafenib counteracts TGF-b1-induced
EMT and cell migration in A549 adenocarcinoma epithelial cells
and provide a possible explanation for its effects with regard to
tumor control and reduced cancer metastasis.
Sorafenib Largely Restores the Changes of Histone
Modifications during EMT
The findings above prompted us to further explore the
underlying epigenetic mechanisms of EMT regulation by
sorafenib. Histone modifications, but not DNA methylation, had
been previously reported to undergo widespread reprogramming
during EMT mediated by TGF-b1 [8]. We therefore focused on
investigating dynamic changes in histone modifications on a
genome-wide scale. We chose conventional markers of active
euchromatin such as H3K9ac and H3K4me3, and contrasted
their architecture with the repressive structures associated with
H3K27me3 and H3K9me3. The profiling of these four selected
histone modifications was performed using ChIP-seq on control,
TGF-b1-treated and TGF-b1+sorafenib-treated cells (as indicated
in Figure 1A and Figure S1). The experiments produced
approximately 15 to 26 million uniquely mapped reads per
chromatin modification (Table S1). Visualization of the ChIP
signals indicated a high enrichment of H3K9ac and H3K4me3
around the transcription start sites (TSSs) and a broad distribution
of the H3K27me3 and H3K9me3 signals in genic regions (Figure
S2A). Subsequently, we focused on the changes of histone
modifications in the promoter regions, which are important
regulatory elements for gene transcription. We began by looking at
the overall signal distribution of histone modifications in the A549
cells under different treatment conditions. Interestingly, we
observed a global decrease in H3K9ac and a prominent increase
of H3K27me3 upon TGF-b1 stimulation. The loss of H3K9ac
and the gain of H3K27me3 in TGF-b1-treated cells were largely
reversed after treatment with sorafenib (Figure S2B). Moreover,
compared to control epithelial cells, the H3K9ac level was
particularly highly up-regulated in TGF-b1+sorafenib-treated
cells, indicating that sorafenib has much broader function than
is currently known as an effective inhibitor against TGF-b
signaling. Nevertheless, it appears that to a certain extent sorafenib
exerts considerable reciprocal effects on H3K9ac and H3K27me3
changes that are stimulated by TGF-b1 during EMT. On the
other hand, such effects on the active H3K4me3 mark and the
repressive H3K9me3 mark were not as obvious on the global
scale.
We further performed pair-wise comparisons among the three
treatment conditions to assess the changes in the histone
modifications within specific genomic regions during EMT.
Significant differential histone modification regions (DHMRs)
were defined based on strict criteria (see Methods). By cross-
matching the DHMRs identified between control and TGF-b1-
treated cells with those between control and TGF-b1+sorafenib-
treated cells, we found that 44%–72% of the DHMRs between
control and TGF-b1-treated cells disappeared in the TGF-
b1+sorafenib-treated cells (Figure 2C). Furthermore, the high
divergence in the DHMR signals between control and TGF-b1-
treated cells (Figure 2A) was largely restored by the treatment with
sorafenib, as indicated by the scatter plots for the DHMR signals
in corresponding regions between control and TGF-b1+sorafenib-
treated cells (Figure 2B). We subsequently screened the genes that
contained DHMRs in their promoter regions, which we term as
differential histone modification genes (DHMGs). Cross-matching
of the DHMGs revealed only a small proportion (21%–49%) of
common DHMGs, among which the changes in histone modifi-
cations in a portion of the DHMGs between control and TGF-
b1+sorafenib-treated cells were reciprocal to those between
control and TGF-b1-treated cells (as indicated by the ‘‘yellow’’
cycle in Figure 2D). By combining the reciprocal DHMGs with the
DHMGs that were specific to TGF-b1-treated cells, we obtained a
collection of approximately 70%–91% of DHMGs that were
reciprocally regulated by sorafenib for use in subsequent analysis.
Sorafenib Significantly Suppresses Coordinated
Epigenetic Switching of Critical EMT-associated Genes
Next, we used the set of DHMGs identified above to examine
whether sorafenib exerts functional effects on the progress of
EMT. To address this question, KEGG (Kyoto Encyclopedia of
Genes and Genomes) pathway enrichment analysis was performed
[15]. DHMGs and enriched pathways are summarized in Dataset
Epigenetic Mechanism under Sorafenib Inhibits EMT
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S1. As expected, most of the top enriched pathways were involved
in EMT-related functions, including cell adhesion, cytoskeleton
remodeling, cell migration, MAPK signaling and EMT-related
cancers, which is in good accordance with the results from
DHMGs during EMT upon stimulation with TGF-b1 (Dataset
S2). Notably, many of the DHMGs regulated by the two active
marks (H3K4me3 and H3K9ac) were identified as enriched. A
secondary measure of pathway enrichment analysis by DAVID
(The Database for Annotation, Visualization and Integrated
Discovery) revealed similar results (Dataset S3), indicating
sorafenib exerts potent effects on the progress of EMT via
epigenetic mechanism.
In previous studies, many clusters of genes were found to play
important roles during EMT progress. To gain further insight into
the impact of sorafenib on EMT, we next focused on the
epigenetic switching of three sets of genes that are critical for
EMT. Among these EMT-associated genes, a switch from E-
cadherin to N-cadherin expression is the most well characterized
event [16]. In our results, the H3K4me3 and H3K9ac levels
within the promoter region of E-cadherin were decreased and both
these two active modifications in the promoter of N-cadherin were
increased during EMT, which is consistent with the changes in
their expression levels (Figure 3A). In addition, we found that
another two adhesion molecules (OB-cadherin and CDH19) from
the cadherin superfamily showed increased levels of H3K4me3
and H3K9ac in their promoter regions. Impressively, EMT
induced these epigenetic switching and expression profiles of
cadherins, and these changes could be significantly blocked by
sorafenib (Figure 3A). The TGF-b signal triggers EMT primarily
via a canonical Smad-dependent mechanism and induces the
transcription of target genes responsible for EMT, including
EMT-related transcription factors and extracellular matrix pro-
teins (ECM) [17,18]. Here, compared to cells undergoing EMT,
sorafenib largely reduced the degree of H3K4me3 and H3K9ac
marks within the promoters of TGF-b1, Snail and Slug, except
H3K9ac of Snail (Figure 3B). As for Snail, the H3K9ac level within
the promoter was decreased during EMT and this alteration was
almost completely counteracted by sorafenib. Accumulation of
ECM proteins promotes the progression of cancer by promoting
cellular transformation and metastasis [19]. Based upon epigenetic
profiling, we found that the promoter regions of several ECM
genes associated with cell migration (for example, COL1A1,
COL5A1 and COL22A1) were dominated by H3K4me3 and
H3K9ac following EMT and these switches were also significantly
suppressed by sorafenib (Figure 3C). Additionally, we performed
real-time qPCR to detect the consistency between epigenetic
switching and gene expression profiling, and found that sorafenib
could significantly suppress coordinated switching of critical EMT-
associated genes at both epigenetic and expression level. Other
than the selected genes above, the epigenetic modifications of
other EMT-related genes were substantially regulated by sorafenib
(Dataset S1), indicating that sorafenib functions as a potent
inhibitor of EMT through the epigenetic modulation of multiple
EMT-associated genes.
We further employed another lung carcinoma cell line (PC9
cells) to corroborate and extend the epigenetic mechanism of anti-
EMT actions of sorafenib. Similar to the findings in A549 cells,
PC9 cells treated with TGF-b1 also underwent EMT and this
process could be counteracted by sorafenib (Figure S3A). We next
used ChIP-qPCR analysis to evaluate the changes of H3K4me3
histone modification on the promoters of EMT-associated genes.
As shown in Figure S3B, sorafenib significantly suppressed
Figure 1. Treatment with sorafenib counteracts TGF-b1-induced EMT in A549 alveolar epithelial cells. (A) A549 cells were treated with
TGF-b1 (5 ng/mL) and/or sorafenib (5 mM) for 48 h. Cells treated with vehicle only (DMSO) served as controls. EMT was determined based on
morphological changes using a conventional phase-contrast microscope. The scale bar represents 100 mm for each section. (B) A549 cells were
treated with TGF-b1 (5 ng/mL) and sorafenib (5 mM), lysed at different time points (0, 24 and 48 h) and immunoblotted using antibodies as indicated.
(C) A549 cells were incubated with TGF-b1 (5 ng/mL) and increasing concentrations of sorafenib (1, 2 and 5 mM) for 48 h. The inhibitory effect of
sorafenib on EMT was then assessed by Western blotting to detect the expression levels of related markers, including E-cadherin and fibronectin.
doi:10.1371/journal.pone.0064954.g001
Epigenetic Mechanism under Sorafenib Inhibits EMT
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switching of many EMT-associated genes in PC9 cells (p,0.05, t-
test), suggesting a general anti-EMT action of sorafenib.
Sorafenib Potentiates Histone Acetylation by Regulating
the Expression Levels of HATs and HDACs
The results presented above indicate that the inhibition of EMT
by sorafenib was accompanied by an increase in the activating
histone modification H3K9ac (Figure S2), which led us to further
examine the impact of sorafenib on the expression of histone-
modifying enzymes. H3K9ac is specifically mediated by GCN5
and PCAF, which are two highly homologous histone acetyltrans-
ferases (HATs) expressed in mammals [20], therefore, we
hypothesized that sorafenib could potentially affect the expression
levels of these two HATs. To test this hypothesis, we employed
Figure 2. Sorafenib substantially reverses the histone modification changes associated with TGF-b1-induced EMT. We performed
genome-wide analyses of four selected histone modifications in A549 cells under different treatment conditions as indicated in Figure 1A. (A, B)
Scatter plots of the average ChIP signals of the significant DHMRs for each histone modification (H3K4me3, H3K9ac, H3K9me3 and H3K27me3) that
were identified from comparisons between control and TGF-b1-treated cells. The X-axis indicates the average ChIP signal value of the DHMRs in
control cells, while the Y-axis indicates the ChIP signal values of the same DHMRs in TGF-b1-treated cells (A) or in TGF-b1+sorafenib-treated cells (B).
Each green spot indicates a DHMR. (C) Venn diagrams showing the relationship between DHMRs identified during EMT (blue), DHMRs identified
between control and TGF-b1+sorafenib-treated cells (pink) and their intersection (dark magenta). (D) Venn diagrams showing the results of cross-
matching DHMGs identified during EMT (blue) and DHMGs identified from a comparison between control and TGF-b1+sorafenib-treated cells (pink).
The common DHMGs are indicated as the intersection (dark magenta), A portion of the genes shown in (dark magenta) contain reciprocal changes
between DHMGS identified during EMT (blue) and DHMGs identified from a comparison between control and TGF-b1+sorafenib-treated cells (pink),
and these are indicated with a yellow color.
doi:10.1371/journal.pone.0064954.g002
Epigenetic Mechanism under Sorafenib Inhibits EMT
PLOS ONE | www.plosone.org 4 May 2013 | Volume 8 | Issue 5 | e64954
real-time qPCR to detect the changes in the expression of HATs
during EMT, and found that the transcriptional level of GCN5 was
up-regulated in response to external TGF-b1 stimulation. More-
over, exposure of A549 epithelial cells to sorafenib eventually
resulted in a significant increase in the expression of GCN5 but had
only a subtle effect on the mRNA level of PCAF (Figure 4A),
suggesting that sorafenib increases the activating histone modifi-
cation H3K9ac in A549 epithelial cells through the selective
upregulation of GCN5 transcription.
Because histone deacetylases (HDACs) also contribute to
chromatin remodeling by catalyzing the removal of acetyl groups
on the NH2-terminal lysine residues of the core nucleosomal
histones [21], we subsequently evaluated the involvement of
sorafenib in the modulation of HDAC expression. As shown in
Figure 4B, the expression levels of the HDACs (HDAC1, HDAC2,
HDAC4, HDAC5 and HDAC8) were enhanced during EMT,
whereas these changes were reciprocally blocked in TGF-
b1+sorafenib-treated A549 cells, suggesting that sorafenib acts as
a potential inhibitor of a large group of HDACs. Taken together,
these results show that sorafenib potentiates the activating histone
modification H3K9ac by regulating the expression levels of
histone-modifying enzymes.
Discussion
As the first oral agent in cancer therapy, sorafenib has been
approved by the FDA for patients with several types of tumors
since 2005 [10,11]. Previous studies have heretofore focused on
the ability of sorafenib to potently inhibit tumor growth and
Figure 3. Sorafenib significantly suppresses coordinated epigenetic switches of critical EMT-associated genes. (A) Distribution of
histone modification signals in the 4,000 bp promoter regions around the transcriptional start sites (TSS) (left) and gene expression (right) of E-
cadherin, N-cadherin, OB-cadherin and CDH19 in control (green), TGF-b1-treated (red) and TGF-b1+sorafenib-treated cells (blue). (B) Distribution of
histone modification signals in the promoters (left) and gene expression (right) of TGF-b1, Snail and Slug in control, TGF-b1-treated and TGF-
b1+sorafenib-treated cells. (C) Distribution of histone modification signals in the promoters (left) and gene expression (right) of COL1A1, COL5A1 and
COL22A1 in control, TGF-b1-treated and TGF-b1+sorafenib-treated cells. Significant differential histone modification regions (DHMRs) induced during
EMT and reciprocally regulated by sorafenib are marked by dotted frames. Gene expression data are representative of three similar experiments and
displayed as the mean 6 SE. **, p,0.01 as evaluated using the Student’s t-test.
doi:10.1371/journal.pone.0064954.g003
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angiogenesis through blocking a number of receptor tyrosine
kinases [10,11,22]. However, in addition to the established
functions in clinical trials, sorafenib likely has much broader
effects than is currently known. The present study sheds light on
the novel capacity of sorafenib to reverse coordinated epigenetic
switching at both the global level and the local level of critical
EMT-associated genes that have been previously shown to play
crucial roles during EMT, providing a possible epigenetic
mechanism for its clinical benefits in patients with cancer
metastasis, organ fibrosis and other EMT-related diseases. Using
A549 carcinoma epithelial cells as an in vitro model, we found that
treatment with sorafenib in during TGF-b1-induced EMT
resulted in a loss of active histone markers (H3K4me3 and/or
H3K9ac) at the promoters of TGF-b1, Smad2/3 and downstream
EMT mediators such as Snail and Slug (Figure 3). Combined with
our previous finding that sorafenib disrupts the phosphorylation of
Smad2/3 and STAT3 [12], we suggest that sorafenib interferes
with TGF-b1-induced EMT via a dual mechanism–first via the
direct inhibition of targeted kinase phosphorylation and then via
transcriptional repression of EMT-related genes by epigenetic
regulation. In addition to TGF-b signaling, we found that
sorafenib inhibits the coordinated epigenetic switching of a broad
range of signaling pathways that have been attributed to many
oncogenic disorders, including Ras/Raf/MAPK and ErbB signal
transduction (Dataset S1). Earlier studies on the resistance and
sensitivity to sorafenib investigated gene-drug correlations by
transcription profiling [23,24,25]. Here, we uncover a novel effect
of sorafenib on the genome-wide profilings of epigenetic modifi-
cations in human lung adenocarcinoma cells, which holds
enormous promise for the study of pharmacoepigenetics and
interindividual variation in drug response and toxicity. A more
detailed set of such investigations is therefore highly desirable to
identify new epigenetic candidates that are sensitive to sorafenib
and to ultimately develop personalized treatment of human
malignancies.
Here, we provide the first blueprint of the dynamic pattern of
epigenetic changes to EMT-associated genes during TGF-b1-
induced EMT. The functional disturbance of cell-cell contacts that
correlate with the loss of E-cadherin expression is a prerequisite for
EMT, invasion and metastasis of tumor cells. The epigenetic
silencing of E-cadherin has been well studied in many laboratories.
For example, the evidence was first presented that the promoter
hypermethylation was a possible mechanism of E-cadherin
inactivation and later pointed to progressive histone modifications
including H3K4me3 and H3K27me3 [26,27,28]. Our findings
add to the short list of epigenetic silencing mechanisms of E-
cadherin and show that a significant loss of H3K4me3 and
H3K9ac accompanies the decrease in E-cadherin expression during
EMT in lung epithelial cells. Impressively, we found that the
expression of OB-cadherin and CDH19, two members of the
cadherin superfamily, were clearly increased during EMT and
were accompanied by an increase in both H3K4me3 and H3K9ac
Figure 4. Sorafenib regulates the expression levels of HATs and HDACs. After treatment with TGF-b1 (5 ng/ml) in the absence or presence
of sorafenib (5 mM) for 24 h or 48 h, A549 cells were subjected to real-time qPCR analysis to determine the effect of sorafenib on the expression levels
of (A) HATs and (B) HDACs. Normal A549 cells without any treatment (at 0 h) were taken as the control. The quantitative ratios are shown as relative
values that were normalized to GAPDH expression. The data are representative of six similar experiments and are displayed as the mean 6 SE. **,
p,0.01 as evaluated using the Student’s t-test.
doi:10.1371/journal.pone.0064954.g004
Epigenetic Mechanism under Sorafenib Inhibits EMT
PLOS ONE | www.plosone.org 6 May 2013 | Volume 8 | Issue 5 | e64954
active marks at their promoters (Figure 3A). Many reports indicate
that OB-cadherin contributes to EMT in pulmonary fibrosis and
promotes the metastasis of several types of cancer cells [29], while
very little information on the role of CDH19 is available. Due to
the expression changes of CDH19 and the influence of sorafenib
on the histone modification profiling at its promoter during EMT,
we hypothesize that CDH19 could act as another vital mediator of
EMT and a novel therapeutic target for the treatment of organ
fibrosis and cancer. Additional investigation is certainly necessary,
however.
In general, histone acetylation enables genes to be expressed,
and HDAC1/2 activity is required to repress epithelial markers
during cancer cell invasion and metastasis [30]. Recently, the
inhibition of HDACs has become a focus of attention for the
discovery and development of anticancer drugs because they have
emerged as potential strategies for reversing the aberrant
epigenetic changes that are associated with tumorigenesis
[31,32]. Till now, several classes of HDAC inhibitors have been
approved to be successfully used as anti-cancer agents, some of
which could be synergized with sorafenib in a combination
therapy for diverse preclinical models of cancer [33,34]. However,
very little is known regarding the molecular mechanisms that
underlie the synergistic interactions between sorafenib and HDAC
inhibitors. In the current study, we interpret that these synergistic
effects are at least partly because of a dual role of sorafenib in the
increase of HAT expression and a decrease in HDAC expression
(Figure 4). In addition to the impact of sorafenib on the expression
of histone-modifying enzymes, we also observed that sorafenib
attenuated the expression of DNA methyltransferases (DNMTs)
(Figure S4). Based on these findings, the anticancer mechanism of
sorafenib could be considerably broader and more complicated
than originally thought to be a multikinase inhibitor.
To the best of our knowledge, this work presents the first report
of sorafenib inhibiting TGF-b1-induced EMT through a possible
epigenetic mechanism and shows that sorafenib largely reverses
the coordinated histone modifications and subsequent epigenetic
switching of relevant genes that are critical for EMT. As in other
physiological contexts, epigenetic reprogramming during EMT is
mediated by widespread changes in histone modifications. Further
studies are needed to assess the consistency of these epigenetic
changes between cell lines and in animal models, and to eventually
understand the utility of epigenetically changed genes as diagnostic




Recombinant human TGF-b1 was purchased from R&D
Systems (Minneapolis, MN, USA). Sorafenib (Nexavar, BAY 43-
9006) was manufactured by Bayer Pharmaceuticals (West Haven,
CT, USA). Primary antibodies against H3K9ac, H3K4me3,
H3K27me3 and H3K9me3 were purchased from Millipore
(Bedford, MA, USA). The rabbit monoclonal antibody against
E-cadherin was purchased from Cell Signaling Technology
(Beverly, MA, USA). Other primary antibodies described in this
paper, including the anti-fibronectin and anti-b-actin antibodies,
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Cell Culture
Human alveolar epithelial A549 cells were obtained from
ATCC (Manassas, VA, USA) and cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) (Biochrom, Berlin, Germany) at 37uC with 5% CO2.
Western Blotting
To detect the protein levels of epithelial and mesenchymal
markers, cells treated as indicated were lysed with 200 ml of lysis
buffer and subjected to western blot analysis [35]. Approximately
50 mg of total protein was separated by SDS-PAGE, transferred to
a PVDF membrane and incubated with the appropriate antibodies
as indicated in the figure legends. The protein bands were
visualized using an enhanced chemiluminescence (ECL) detection
kit (Amersham).
Chromatin Immunoprecipitation Sequencing
Chromatin immunoprecipitation (ChIP) was performed as
previously described [36]. Briefly, cells were rinsed with room
temperature PBS and cross-linked by 1% formaldehyde following
sonication by a BioruptorTM200 to generate chromatin fragments
between 100 and 500 bp. The solubilized chromatin fragments
were then immunoprecipitated with antibodies against H3K9ac,
H3K4me3, H3K27me3 and H3K9me3, respectively. The ChIPed
DNA was used for cluster generation and standard single-end
sequencing with 50 bp reads (SE50) using Illumina Hiseq 2000.
Processing of ChIP-sequencing Reads
After SE50 sequencing, the Illumina reads were post-processed
and aligned to the human reference genome (UCSC hg19) using
SOAP (Short Oligonucleotide Analysis Package) 2.01 with default
parameters that excluded reads with more than five mismatched
bases [37]. Reads that were mapped to more than one position in
the genome were then filtered out. Multiple reads mapping to the
same position were counted only once to remove potential bias
from PCR. The uniquely mapped single-end reads were then
extended to 150 bp to approximate the average size of the
sequenced fragments, and these extended reads were used for
subsequent analysis. We calculated the number of sequencing
reads covering a specific base as the signal value for the histone
modification for that base in the genome, and then we normalized
the signal by equalizing the total data amount to 1 G bp for all
samples.
Defining the Differential Histone Modification Regions
Differential histone modification regions (DHMRs) for sample-
to-sample comparisons were identified based on three strict
criteria: First, the whole genome was partitioned into 100-bp long
bins, and the average ChIP signal for each bin was calculated.
Initially, the ChIP signal values from five bins were subjected to
double t-test. If the p-values from the double t-test were less than
0.01, then these 5 bins were used as a seed window to slide across
the genome with a 1 bin step size. Double t-test was performed for
each step until a p-value of .0.01 was encountered or the number
of bins reached fifty. Second, only the regions that were identified
as differentially enriched based on statistical analysis and that
possessed a minimum of a 2-fold change in the ChIP signal
between the two samples were kept. The differential regions that
were separated by gaps of size ,1kb were further merged. Finally,
we applied an algorithm previously described by Adli et al to
evaluate signal enrichment in these regions with small adjustments
[38]. Briefly, we first established the background by calculating the
mean signal value of an extended region of 10kb covering the
differential region identified above. Then, for each 100-bp window
sliding across each differential region in 1bp steps, we calculated a
Poisson p-value by comparing the window value to the
background. For H3K4me3 and H3K9ac, windows with Poisson
p-value ,10E25 were identified as enriched, and for H3K9me3
and H3K27me3, windows with Poisson p-value ,10E23 were
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identified as enriched. The differential regions that did not contain
enriched regions in both of the samples were filtered out.
Pathway Enrichment Analysis
We collated a set of 25,489 RefSeq genes (US National Center
for Biotechnology Information; April 18, 2010 update). Pathway
enrichment analysis was performed using the KEGG (Kyoto
Encyclopedia of Genes and Genomes) web server (http://bioinfo.
vanderbilt.edu/webgestalt/) and the DAVID (Database for
Annotation, Visualization and Integrated Discovery) web server
(http://david.abcc.ncifcrf.gov/).
Quantitative Real-time PCR and Statistical Analysis
Total RNA isolation and reverse transcription were performed
as previously described [35]. Primers for real-time quantitative
PCR (RT-qPCR) were designed using Primer 5 software and listed
in Table S2. Real-time qPCR analysis was performed on ABI
Prism 7700 (Applied Biosystems, Tokyo, Japan) using SYBR
Green real-time PCR master mix (Toyobo Co., Japan). Each
measurement was repeated at least in triplicate and normalized to
the corresponding GAPDH content values. Relative expression
levels of objective mRNAs were calculated using the DDCt
method. For gene-specific ChIP analyses, RT-qPCR was used to
determine the enrichment of immunoprecipitated DNA relative to
the input DNA using gene-specific primer sets. Primers were
designed based on differential histone modification regions
(DHMRs) in promoters (as indicated in Figure 3) and listed in
Table S3. The assays were carried out in three replicates and
relative histone modification fold change was calculated for each
sample using the DDCt method. All data are presented as the
mean values6 S.E. Comparisons were made using the Student’s t-
test and a two-sided p-value ,0.05 was considered to indicate
statistical significance.
Data Deposition
The ChIP-seq data generated for this work have been deposited
in the NCBI Gene Expression Omnibus (GEO) (http://www.ncbi.
nlm.nih.gov/geo/) and are accessible through GEO Series
accession number GSE41479.
Supporting Information
Figure S1 Sorafenib abolished the migratory capacity of
A549 alveolar epithelial cells. A549 cells cultured with TGF-
b1 (5 ng/ml) in the absence or presence of sorafenib (5 mM) were
subjected to in vitro scratch assay with images captured at 0 h and
24 h after incubation using a phase-contrast microscope. The edge
of the scratch is marked by imaginary dashed lines.
(TIF)
Figure S2 Overview of histone modifications in the
genic and promoter regions. (A) Distribution of histone
modification signals in genic regions for H3K4me3, H3K9ac,
H3K27me3 and H3K9me3. The mRNA region of each gene
(from TSS to TTS) was divided into 100 portions, and the up-5k
and down-5k region of each gene was divided into 25 portions,
respectively. The X-axis indicates the relative distance to the TSS,
the Y-axis indicates the intensity of each histone mark and the
curve represents the mean signal of all genes in this region. (B) Box
plots show the intensities of histone modification signals in the
promoter regions of all genes. The promoter is defined as a region
crossing upstream 2000 base pairs (bp) and downstream 2000 bp
of the transcriptional start site (TSS). The black line in the box
represents the mid-value of the signals for all of the promoters. Z-
test was used to identify significant differences between control and
TGF-b1-treated cells or between control and TGF-b1+sorafenib-
treated cells. Significance is indicated by ** based on a threshold of
p-value ,1E-5.
(TIF)
Figure S3 Treatment with sorafenib counteracts TGF-
b1-induced EMT in human lung adenocarcinoma PC9
cells. (A) PC9 cells were treated with TGF-b1 (5 ng/mL) and/or
sorafenib (5 mM) for 48 h, lysed and immunoblotted using
antibodies as indicated. (B) H3K4me3 modification and RNA
expression changes in PC9 cells. The data are representative of
three similar experiments and are displayed as the mean 6 SE. **,
p,0.01 as evaluated using the Student’s t-test.
(TIF)
Figure S4 Sorafenib regulates the expression levels of
DNMTs. After treatment with TGF-b1 (5 ng/ml) in the absence
or presence of sorafenib (5 mM) for 24 h and 48 h, A549 cells were
subjected to real-time qRT-PCR analysis to determine the effect of
sorafenib on the expression levels of DNMT1, DNMT3A and
DNMT3B. Normal A549 cells without any treatment (at 0 h) were
taken as the control. The quantitative ratios are normalized to the
expression of GAPDH. The data are representative of six similar
experiments and are displayed as the mean 6 SE. **, p,0.01 as
evaluated using the Student’s t-test.
(TIF)
Table S1 Summary of uniquely mapped reads per
histone marker.
(XLS)
Table S2 Optimized primers used for real-time qPCR.
(XLS)
Table S3 Primers used for H3K4me3 ChIP-qPCR.
(XLS)
Dataset S1 DHMGs reciprocally regulated by sorafenib
during EMT and KEGG Pathway Enrichment Analysis.
The file contains the lists of DHMGs including H3K4me3,
H3K9ac, H3K9me3 and H3K27me3 that are reciprocally
regulated by sorafenib during EMT, and KEGG Pathway
Enrichment Analysis of these DHMGs.
(XLS)
Dataset S2 DHMGs during EMT and KEGG Pathway
Enrichment Analysis. The file contains the lists of DHMGs
during EMT including H3K4me3, H3K9ac, H3K9me3 and
H3K27me3, and KEGG Pathway Enrichment Analysis of these
DHMGs.
(XLS)
Dataset S3 DAVID Pathway Enrichment Analysis of
DHMGs reciprocally regulated by sorafenib during
EMT. The file contains DAVID Pathway Enrichment Analysis
of DHMGs reciprocally regulated by sorafenib during EMT.
(XLS)
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